Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7101993 | BIOGEN IDEC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(6 months ago) | |
US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(3 years from now) | |
US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
May, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(1 year, 8 months from now) | |
US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(1 year, 8 months from now) | |
US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(6 years from now) | |
US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(6 years from now) | |
US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(9 years from now) | |
US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(11 years from now) |
Spinraza is owned by Biogen Idec.
Spinraza contains Nusinersen Sodium.
Spinraza has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Spinraza are:
Spinraza was authorised for market use on 23 December, 2016.
Spinraza is available in solution;intrathecal dosage forms.
Spinraza can be used as treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; treatment of type iii spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy, treatment of type iii spinal muscular atrophy; treatment of spinal muscular atrophy; treatment of infantile-onset spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna, treatment of spinal muscular atrophy, treatment of spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna, treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; treatment of spinal muscular atrophy, treatment of infantile-onset spinal muscular atrophy.
The generics of Spinraza are possible to be released after 11 September, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy; Treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; Treatment of spinal muscular atrophy by increasing exon-7 inc...
Dosage: SOLUTION;INTRATHECAL